Robert Straka

COP - Image - Size 3 - COP - straka robert

Robert Straka, B.Sc., Pharm.D., FCCP

Academic Title

Professor and Head
Experimental and Clinical Pharmacology

Education

Pharmacy School
Pharm.D. College of Pharmacy, University of Minnesota, 1985
Fellowship
Cardiovascular Pharmacokinetics, University of Tennessee, 1987
Bachelor's
Pharmacy, University of Toronto, Ontario, Canada, 1983
Other Education
Sabbatical, Cardiovascular Pharmacogenomics, University of Florida, 2006-2007

Contact Info

Email
strak001@umn.edu

Phone
612-624-5663

Fax
612-625-3927

Office Address

7- 115B Weaver-Densford Hall

Mailing Address

University of Minnesota
College of Pharmacy
Department of Experimental and Clinical Pharmacology
7-115 Weaver-Densford Hall
308 Harvard St. SE
Minneapolis, MN 55455

Research Interests

  • Cardiovascular Pharmacotherapy
  • Pharmacogenomics
  • Pharmacodynamics and Pharmacokinetics
  • Drug Metabolism
     

Research Projects

My research interests are focused on optimizing the use of therapeutic agents used for the prevention and treatment of cardiovascular disease by investigating pharmacogenetic, pharmacokinetic and pharmacodynamic sources of variability in response. Although primarily interested in cardiovascular Therapeutics (eg the GOLDN Study), my investigations have included environmental sources of variability in response as well as therapeutic agents used to treat conditions other than cardiovascular disease. We are also interested in research related to ethnicity-based sources of drug response variability. Understanding sources of variability in drug response may prove helpful in optimizing the achievement of therapeutic targets - a goal which is common to all those interested in optimizing clinical outcomes.

Therapeutic Areas of Interests

Hyperlipidemia, Hypertension and Heart Failure

Downloads

Links 

 

Publications

1. Trottier J, Caron P, Straka, RJ, Barbier O. Profile of Serum Bile Acids in Noncholestatic Volunteers: Gender-Related Differences in Response to Fenofibrate. Clinical Pharmacology & Therapeutics. 2011August 90 (2):279-286 PMID 21716269

2. Kraja AT, Province MA, Straka RJ, Ordovas JM, Borecki IB, Arnett DK. Fenofibrate and metabolic syndrome.
Endocr Metab Immune Disord Drug Targets. 2010 Jun 1;10(2):138-48.PMID 20406163

3. Tsai MY, Ordovas JM, Li N, Straka RJ, Hanson NQ, Arends VL, Arnett D. Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network. Mol Genet Metab. 2010 Jun;100(2):118-22. Epub 2010 Mar 6.PMID: 20346718

4. Straka RJ, Liu LZ, Girase PS, DeLorenzo A, Chapman RH. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting. Cardiovascular Diabetology. 2009 Sep 26;8:53. PMID: 19781099

5. Tojcic J, Benoit-Biancamano MO, Court MH, Straka RJ, Caron P, Guillemette C. In vitro glucuronidation of fenofibric acid by human UGTs and liver microsomes. Drug Metabolism and Disposition 2009;11:2236-2243. PMID 19661212

6. Perez-Martinez P, Corella D, Shen J, Arnett DK, Yiannakouris N, Tai ES, Orho-Melander M, Tucker KL, Tsai M, Straka RJ, Province M, Kai CS, Perez-Jimenez F, Lai CQ, Lopez-Miranda J, Guillen M, Parnell LD, Borecki I, Kathiresan S, Ordovas JM. Association between glucokinase regulatory protein (GCKR) and apolipoprotein A5 (APOA5) gene polymorphisms and triacylglycerol concentrations in fasting, postprandial, and fenofibrate-treated states. Am J Clin Nutr. 2009;89:391-399. PMID: 19056598

7. Liu Y, Ordovas JM, Gao G, Province M, Straka RJ, Tsai MY, Lai CQ, Zhang K, Borecki I, Hixson JE, Allison DB, Arnett DK. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the Genetics of Lipid-Lowering Drugs and Diet Network study. Pharmacogenet Genomics. 2009;19:161-169. PMID: 19057464

8. Liu Y, Ordovas JM, Gao G. Province M. Straka RJ, Tsai MY, Lai CQ, Zhang K, Borecki I, Hixson JE, Allison DB, Arnett DK The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions. Journal of Human Genetics 2008;53:709-717. PMID 18542840

9. Shen J. Arnett DK, Parnell LD, Peacock JM, Lai CQ, Hixon JE, Tsai MY, Province MA, Straka RJ, Ordovas JM. Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: The GOLDN Study. Diabetes Care. 2008;31:910-915. PMID: 18285551

10. Smith JA, Arnett DK, Kelly RJ, Ordovas JM, Sun YV, Hopkins PN, Hixson JE, Straka RJ, Peacock JM, Kardia SLR. The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment. Euro J Hum Gen. 2008;16: 603-613. PMID: 18212815

11. Straka RJ, Mamdani M, Damen J, Kuntze CEE, Liu LZ, Botteman MF, Koren MJ. Economic impacts attributable to the early clinical benefit of atorvastatin therapy – a US managed care perspective. Curr Med Res Opin. 2007;23(7):1517-29. PMID: 17535539

12. Lai CQ, Arnett DK, Corella D, Straka, RJ, Tsai MY, Peacock JM, Adiconis X, Parnell LD, Hixon JE, Province MA, Ordovas JM. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: The GOLDN study. Arterioscler Thromb Vasc Biol. 2007;27(6):1417-25. PMID: 17431185

13. Kaila N, Straka RJ, Brundage RC. Mixture models and subpopulation classification: A pharmacokinetic simulation study and application to metoprolol CYP2D6 phenotype. J Pharmacokinetics Pharmacodynamics. 2007;34(2):141-56. PMID: 17053980

14. Straka RJ, Burkhardt RT, Lang NP, Hadsall KZ, Tsai MY. Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects. J Clin Pharmacol. 2006;46(7):802-11. PMID 16809806

15. Straka RJ, Burkhardt RT, Lang NP, Vang T, Hadsall KZ, Tsai MY Verified predominance of slow acetylator phenotype N-acetyltransferase 2 (NAT2) in a Hmong population residing in Minnesota. Biopharm Drug Dispos. 2006;27(6):299-304. PMID: 16799928

16. Straka RJ, Taheri R, Cooper SL, Smith JC. Achieving cholesterol target in a managed care organization (ACTION) trial. Pharmacotherapy. 2005;25(3):360-71. PMID: 15843283

17. Straka RJ, Taheri R, Cooper SL, Tan AW, Smith JC. Assessment of hypercholesterolemia control in a health care organization. Pharmacotherapy. 2001;21(7):818-27. PMID: 11444578

18. Straka RJ, Fish JP, Benson SR, Suh JT. Patient self-reporting of compliance does not correspond with electronic monitoring: an evaluation using isosorbide dinitrate as a model drug. Pharmacotherapy 1997:17(1);126-33. PMID: 9017773

19. Straka RJ, Hansen R, Walker P. Predominance of slow acetylators of N-acetyltransferase in a Hmong population residing in the United States. J Clin Pharmacol. 1996;36(8):740-7. PMID: 8877679

20. Straka RJ, Hansen RS, Walker PF. Comparison of the prevalence of the poor metabolizer phenotype for CYP2D6 between 203 Hmong subjects and 280 white subjects residing in Minnesota. Clin. Pharmacol Ther 1995;58(1):29-34. PMID: 7628180

21. Lalonde RL, Straka RJ, Pieper JA, Bottorff MB, Mirvis DM. Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers. J Pharmacokinet Biopharm 1987;15(6):569-82. PMID: 3450842


22. Straka RJ, Lalonde RL, Pieper JA, Bottorff MB, Mirvis DM. Nonlinear pharmacokinetics of unbound propranolol after oral administration. J Pharm Sci 1987;76(7):521-4. PMID: 3668812
 

  • ©2013 Regents of the University of Minnesota. All rights reserved.
  • The University of Minnesota is an equal opportunity educator and employer
  • Last modified on December 3, 2013